What is Jaguar Health's market cap?

Jaguar Health (JAGX) has a market capitalization of $802.6K and trades on NASDAQ.

Who are Jaguar Health's competitors?

Jaguar Health's key competitors include Ironwood Pharmaceuticals, Inc., Merck & Co., Inc., Ardelyx, Inc., and others. These companies compete in similar markets and product categories.

Who does Jaguar Health partner with?

Jaguar Health's notable partners include Future Pak, LLC, Filament Health Corp., Venture Life Group PLC, and others.

What subsidiaries does Jaguar Health have?

Jaguar Health's subsidiaries include Napo Pharmaceuticals, Inc., Napo Therapeutics, S.p.A., Magdalena Biosciences.

Where is Jaguar Health headquartered?

Jaguar Health is headquartered in United States of America and employs approximately 49 people. It has been publicly traded since 2015.

Jaguar Health

JAGX

Jaguar Health is a commercial-stage pharmaceutical company focused on developing and commercializing sustainably derived, plant-based prescription medicines for complex gastrointestinal diseases.

Market cap

$802.64K-77.0%

Table of contents

Earnings

Q4 2025 report

May 20, 2026

Revenue$3.2MMiss by $975.0K EPS-$13.60Beat by $135.50

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

Revenue estimate$4.2M

EPS estimate-$52.15

Competitors

By market cap

Merck & Co.$322.95B+53.0%

ANI Pharmaceuticals$1.8B+23.7%

Ardelyx$1.2B+22.1%

Eton Pharmaceuticals, Inc.$1.2B+188%

Ironwood Pharmaceuticals$643.6M+398%

Zevra Therapeutics, Inc.$574.0M-2.9%

Soligenix, Inc.$5.4M+28.4%

Jaguar Health$802.6K-78.1%

By revenue growth

Zevra Therapeutics, Inc.+201%

Eton Pharmaceuticals, Inc.+79.9%

ANI Pharmaceuticals+37.0%

Ardelyx+18.2%

Ironwood Pharmaceuticals+13.8%

Merck & Co.+2.9%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Ironwood Pharmaceuticals28.26%+38.4pp

Merck & Co.13.59%-13.7pp

ANI Pharmaceuticals9.98%+13.1pp

Eton Pharmaceuticals, Inc.-9.5%+2.7pp

Ardelyx-13.58%+9.9pp

Profile

Jaguar Health is a commercial-stage pharmaceutical company focused on developing and commercializing sustainably derived, plant-based prescription medicines for complex gastrointestinal diseases. The company's core value proposition centers on its proprietary botanical drug platform, specifically utilizing crofelemer to address significant unmet medical needs in both human and animal health, including rare diseases and cancer-related supportive care.

Competitive position

Jaguar Health holds a unique position as a leader in botanical drug development with a significant patent portfolio and FDA-approved products for niche gastrointestinal indications.

GeographiesUnited States, European Union, Middle East

Customer segmentsSpecialty Healthcare Providers, Veterinary Clinics, Pharmaceutical Distributors

Business modelResearch and Development, Licensing, Product Sales

SuppliersSustainable plant sourcing, Botanical raw material suppliers, Contract manufacturing organizations

CustomersSpecialty pharmacies, Hospitals, Veterinary distributors, Licensees

CountryUnited States of America

Listed2015

Employees49.0

CEOLisa A. Conte

SectorHealthcare

IndustryBiotechnology

Websitejaguar.health

FilingsSEC EDGAR

Questions, answered.

What is Jaguar Health's market cap?: Jaguar Health (JAGX) has a market capitalization of $802.6K and trades on NASDAQ.
Who are Jaguar Health's competitors?: Jaguar Health's key competitors include Ironwood Pharmaceuticals, Inc., Merck & Co., Inc., Ardelyx, Inc., and others. These companies compete in similar markets and product categories.
Who does Jaguar Health partner with?: Jaguar Health's notable partners include Future Pak, LLC, Filament Health Corp., Venture Life Group PLC, and others.
What subsidiaries does Jaguar Health have?: Jaguar Health's subsidiaries include Napo Pharmaceuticals, Inc., Napo Therapeutics, S.p.A., Magdalena Biosciences.
Where is Jaguar Health headquartered?: Jaguar Health is headquartered in United States of America and employs approximately 49 people. It has been publicly traded since 2015.